Navigation Links
Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011
Date:1/27/2011

SILVER SPRING, Md., Jan. 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has scheduled its fourth orphan drug designation workshop for academics, biotechnology companies, and those unfamiliar with the process for Feb. 28 – March 1, 2011, in Claremont, Calif. in collaboration with Keck Graduate Institute.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The workshop, co-sponsored by the National Organization of Rare Disorders and the Genetic Alliance, will focus on the process used by the FDA to grant a special status, known as orphan drug designation, for drug products intended to treat rare diseases. Three similar workshops were held in 2010.

Orphan drugs are either drugs or biologics intended for the treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the United States, or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing the drug. Orphan designation qualifies the applicant to receive certain benefits, such as tax credits and marketing incentives, from the federal government in exchange for developing the drug.

During the workshop, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop. FDA staff will provide one-on-one guidance to help participants develop strong applications. Designation requires there be a scientific rationale for expecting the proposed drug to be effective in the treatment, prevention, or diagnosis of that disease or condition.

For more information:

  • FDA: Orphan Drug Workshop

http://www.fda.gov/downloads/Fo
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zimmer Reports Fourth Quarter and 2010 Financial Results
2. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
3. Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
4. Video From AstraZeneca Available on thenewsmarket.com: AstraZeneca Announces Fourth Quarter and Full Year Results 2010
5. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
6. Solta Medical Announces Full Year and Fourth Quarter 2010 Results Release and Conference Call
7. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
8. Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
9. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
10. Medco Announces Date for Release of Fourth-Quarter and Full-Year 2010 Financial Results
11. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... Dec. 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... completion of enrollment in its first Phase 2a ... observations confirmed the 1-month findings that were reported ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... MYL ) today announced that it has ... La Roche Inc. resolving litigation related to XELODA® Tablets, ... Capecitabine Tablets. This product is an orally administered chemotherapeutic ... colorectal cancers. Pursuant to the agreement, ...
... Texas, Sept. 21, 2011 SmallCapVoice.com, Inc. ... Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI), ... medical alarm system that allows the users ... pendant, is now available. The interview can ...
Cached Medicine Technology:Mylan Announces XELODA® Settlement and License Agreement 2A New Audio Interview with Medical Alarm Concepts Holdings, Inc., CEO, Howard Teicher, is now at SmallCapVoice.com 2
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... CARSON CITY, NV (PRWEB) December 15, 2014 ... new powerhouse company, JM Ocean Avenue. JM Ocean ... technology of the Veretekk online automated marketing system. ... by the June 2014 merger of Ocean Avenue and ... a more than $2 Billion per year company. , ...
(Date:12/15/2014)... December 15, 2014 South Florida’s leading urgent ... holidays can be a daze of hassle, hustle, and bustle ... while decking halls, to burns when making special meals and ... that can happen at any time. To prevent this season ... has made a list of helpful and healthful holiday tips ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... , ... Shield of Texas has designated Houston Northwest Medical Center as a Blue Distinction Center for ... ... Northwest Medical Center as a Blue Distinction Center for Knee and Hip Replacement. Blue Distinction ...
... ... ... , ... , , ...
... ... ... , , , , ... ...
... , ... ... , , , ... Avon ...
... The National Institutes of Health has awarded a two-year ... the Bradley Hasbro Children,s Research Center to better understand ... disease (IBD), a condition that causes chronic and painful ... grant, funded by the American Recovery and Reinvestment Act ...
... and health care providers need to step up their ... pressure and better treat those with the condition, which ... half of heart failures in the United States each ... Medicine. Policies that create environments which ...
Cached Medicine News:Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 4Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 2Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 3Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 2Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 3Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 2Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 3Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 4Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 6Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 2Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 3Health News:IOM report declares high blood pressure a neglected disease 2Health News:IOM report declares high blood pressure a neglected disease 3
... Intuition EMR Ophthalmology is a comprehensive ... tailored for ophthalmology practices. Intuition EMR ... but provides the tools to evaluate ... you to make better decisions and ...
... MaximEyes by First Insight is the ... records solution for eye care professionals. ... with Eyefinitys online servicesrequest VSP authorizations, ... MaximEyes offers EMR, scheduling, billing, demographics, ...
... latest in advanced cartridge mixing and delivery ... and mechanically injects all types of bone ... Revolution&trade line-up includes a large selection of ... in difficult to access areas. A new, ...
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
Medicine Products: